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Suummary Several in vitro studies stress a potentially important role of interleukin 4 (IL-4) and the related
gp200-MR6 molecule in the immunological response to cancer and in tumour proliferation. In the present
study, we assessed the expression of gp200-MR6 in primary breast cacrinomas using the MR6 monoclonal
antibody. Results were correlated with tumour parameters (T-,N-stage, histology, grade, oestrogen and
epidermal growth factor (EGF) receptors), and the impact on survival was assessed. Twenty-four out of 110
cases (22%) were positive for gp200-MR6, 62 out of 110 (56%) expressed weak staining and 24 out of 114
(22%) did not stain. The normal breast epithelia were invariably stained for gp200-MR6 showing that down-
regulation or loss of this molecule occurred during the evolution of breast cancer. Gp200-MR6 loss was
independent from differentiation, nodal positivity and oestrogen receptor levels as well as patients' age. Loss of
the gp200-MR6 molecule was more frequent in lobular cases (P=0.03). The overall survival was better,
although not reaching statistical significance, in patients with positive gp200-MR6 expression (92% alive at 5
years compared with 70% for those with weak or no expression, P=0.1). The local relapse-free survival was
independent of gp200-MR6 status. It is concluded that loss of gp200-MR6 may be one of the mechanisms
through which breast cancer cells escape immune surveillance, resulting in an increased metastatic potential and
poorer outcome. Evidence of down-regulation of the gp200-MR6 molecule has implications for IL-4-linked
toxin therapy and, as IL-4 is an inhibitor of breast epithelial growth, may represent loss of a tumour-
suppression mechanism.
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Recent studies have revealed an important role of interleukin
4 (IL-4) and its receptor in carcinogenesis, tumour
proliferation and the immune response against cancer. IL-4
is a member of the cytokine family with-multifunctional
activities on a variety of cell lines. Initially, IL-4 was
described as a B-cell growth factor (Howard et al., 1982),
but subsequent studies showed a wide spectrum of activities
on T lymphocytes, macrophages, granulocytes and epithelial
cells (O'Hara et al., 1987; Monroe et al., 1988; Thornhill et
al., 1990; Toi et al., 1991). Accumulating data from
transfection assays with the IL-4 gene or treatment of cell
lines with IL-4 show that IL-4 has a potent anti-tumoral
activity. In a recent study, IL-4 was proved to be a potent
inhibitor of the B.16 melanoma cell line in mice and was 30%
more potent than IL-2 (Zaloom et al., 1993). Transfection of
mammary adenocarcinoma cell lines to produce IL-4 showed
a correlation between IL-4 production and degree of tumour
inhibition (Tepper et al., 1989). Synergy between IL-4 and
other growth inhibitors has been described (Golumbek et al.,
1991). In previous work, we showed that IL-4 and other
growth inhibitors, such as transforming growth factor beta
(TGF-,B) and tamoxifen, have an additive inhibitory effect on
the growth of colon and breast carcinoma cell lines (Toi et
al., 1992). The potentiation of tumour necrosis factor activity
in breast cancer cell lines by IL-4 has also been observed
(Totpal et al., 1991; Hoon et al., 1991).
Recent studies have shown that transfection of the IL-4
gene into Lewis lung carcinoma (LLC) cells is followed by an
induction of immunity against the tumour (Golumbek et al.,
1991). The production of IL-4 from renal cancer cells induces
a T-cell-dependent systemic immunity against the parental
cancer, providing evidence that IL-4 gene-transfected cancer
cells can be used for cancer immunotherapy (Ohira et al.,
1992). The secretion of IL-4 from NK cells, isolated from
breast cancer tissue or peripheral blood of breast cancer
patients, supports the hypothesis that IL-4 could have a role
in the immunological surveillance of cancer (Lorenzen et al.,
1991).
Further support for the role of IL-4 in tumour
development comes from studies on the IL-4 receptor-
associated gp200-MR6 molecule. This molecule, identified
by MAb MR6, was first described at high levels on human
thymic cortical epithelium; it is also expressed on other
epithelia and at low levels on cells of haemopoietic origin (T
and B lymphocytes and macrophages) (DeMaagd et al., 1985;
von Gaudecker et al., 1989). Co-capping data have
demonstrated an association between gp200-MR6 and the
IL-4-binding chain of the IL-4R (CD124), although the MR6
antibody does not block IL-4 binding (Imami et al., 1995).
Functional studies have shown that MAb MR6 inhibits the
IL-4-induced proliferation of T cells and blocks the IL-4-
dependent switch to IgE production in allergen-stimulated B
cells (Larche et al., 1988). These effects are thought to result
predominantly from inhibition of the expansion/function of
the IL-4-secreting Th2 helper T-lymphocyte subset (Imami et
al., 1994).
These data, together with previous studies indicating that
gp200-MR6 expression is lost with increasing malignancy in
lung and colonic carcinoma, raise the possibility that
expression of this molecule may be useful in disease
prognosis, and that it may function as a tumour suppressor
(Tungekar et al., 1991; Kaklamanis et al., 1992). In breast
cancer, both up-regulation and down-regulation have been
reported (Al Jabaari et al., 1989; Mat et al., 1993).
In this study, we have used the monoclonal antibody MR6
to evaluate immunohistochemically the expression of gp200-
MR6 in human primary breast cancer and its significance in
prognosis. Samples were also analysed for expression of
oestrogen and epidermal growth factor receptors (ER and
EGFR). Patients were followed clinically over several years
(median follow-up time 52 months). Data were analysed in
Correspondence: AL Harris
Received 12 October 1995; revised 24 May 1996; accepted 28 June
1996Loss of interleukin 4 and gp200-MR6 in breast cancer
L Kaklamanis et a!
1628
the context of a range of parameters including age at
presentation, T-stage, N-stage, histology, grade, ER and
EGFR expression.
Materials and methods
Patients
One hundred and ten primary invasive breast cancer
specimens were examined. The median age of our patients
was 53 years and a median follow-up of 52 months was
available (4-7 years). All patients had no detectable
metastatic disease at presentation and underwent partial
mastectomy and radiotherapy or total mastectomy with
axillary sampling and radiotherapy to the involved axilla.
Adjuvant chemotherapy was given to 30 patients with
advanced T-stage, positive lymphadenopathy or with poor
prognostic factors such as ER-/EGFR+ and high grade.
Tamoxifen was given in patients with positive oestrogen
receptor levels (> 10 fmol mg-'). Patients were regularly
followed clinically every 3 months for the first year, 4-
monthly for the second year and 6-monthly thereafter.
Tissues
All tissues were snap frozen in liquid nitrogen and stored at
-70°C. Eighty-one tumours were infiltrative ductal carcino-
mas and 12 were lobular carcinomas, the remaining being of
different histological subtypes. Histological diagnosis and
staging were assessed by light microscopy before immunohis-
tochemistry.
Antibody MR6 immunohistochemistry
The monoclonal antibody MR6 is an IgE mouse reagent that
was raised against an extract ofhuman thymic tissus and shown
to react strongly with thymiccortical epithelial cells (De Maagd
et al., 1985). Using Western blotting, MR6 detects a single
polypeptide of 200 kDa. Antibody co-capping and functional
blocking studies have shown an association between gp200-
MR6 and the CD124 chain of the IL-4R (Larche et al., 1988;
Imami et al., 1994; Imami et al., submitted for publication).
MR6 antibody was detected by means of the alkaline
phosphatase-anti-alkaline phosphatase method (APAAP), as
described previously (Cordell et al., 1984). Briefly, 5-8 mM
acetone-fixed frozen sections were incubated in hybridoma
supernantant at room temperature for 30 min. After washing
in Tris-buffered saline, rabbit antibody against mouse
immunoglobulins was applied for 15 min. The sections were
then washed, and preformed APAAP complexes were added
for a further 15-20 min. The last two stages were repeated
before colour development with naphthol AS-BI phosphate
and new fuchsin. All reactions were terminated after 18-
20 min in substrate. A negative control was included in which
the primary antibody was omitted.
The assessment of staining patterns was done as follows: if
more than 70% of the cancer cell population showed a strong
positivity, results were interpreted as positive (+); if 20-60%
of cells expressed MR6 reactivity, results were considered as
weakly positive (w); and, finally, if <20% of cancer cells was
stained with MR6, results were considered as negative (-).
Oestrogen and EGF receptor assay
The ER content of the tumours was determined using the
dextran-coated method (EORTC Breast Cancer Cooperative
Group, 1980). Tumour specimens were considered to be ER
positive if they contained at least 10 fmol of specific binding
sites per mg of cytosolic protein.
Tumour samples were assayed for EGFR using ligand
binding of ['25I]EGF to tumour membranes (Nicholson et al.,
1988; Fraker et al., 1978). A cut-off value of 20 fmol mg-'
protein was used to differentiate between receptor-positive
and -negative tumours.
Figure 1 Normal breast duct epithelium (arrows) stained invariably positive with the MR6 monoclonal antibody (a, x 250). In situ
(small arrow) and invasive cancer (large arrow) with negative MR6 staining and positive reactivity of the myoepithelial cells (small
arrow) and inflammatory component (b, x 250). Invasive ductal breast cancer with strong and diffuse staining with the MR6
antibody (arrows) (c, x 250). Positive MR6 staining of breast normal epithelium (small arrow) with negative cancer cell staining
(large arrow) (d, x 250).Loss of interleukin 4 and gp200-MR6 in breast cancer
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Statistical analysis
Survival curves were plotted using the method of Kaplan-
Meier, and the log-rank test was used to determine statistical
differences between life tables. A cox proportional hazard
model was used to assess the effect of patients and tumour
variables on survival. A chi-square test was used for testing
relationships between categorical variables. The statistical
analysis was performed using the stata 3.1 Package (Stata
Corporation, TX, USA).
Results
Gp200-MR6 expression
In 43 cases, our samples also contained normal breast tissue.
For all cases, the normal breast epithelium was also positively
stained with MR6 (Figure la). Infiltrating lymphocytes,
macrophages and myoepithelial cells (Figure lb) invariably
showed a positive reactivity.
Twenty-four out of 110 cases (22%) of all breast
carcinomas were positive for gp200-MR6, 62 out of 110
(56%) expressed weak staining and 24 out of 114 (22%) did
not stain with the MR6 antibody. Sixteen out of 81 (20%)
invasive ductal carcinomas and 1 out of 12 (8%) lobular
carcinomas were positively stained for gp200-MR6, showing a
higher incidence of gp200-MR6 loss in lobular histology
(P=0.03). All three medullary, 1 out of 1 mucinous and 3 out
of 12 mixed (ductal/lobular) cases had a strong reactivity for
MR6. Figure Ic presents a case of invasive breast cancer
showing MR6 reactivity. Figure ld shows a gp200-MR6-
negative case, whereas normal epithelium is positively stained.
Table I shows the relationship between gp200-MR6
expression and different tumour variables and patients' age.
No statistically significant correlation was found between the
expression of gp200-MR6 and T-stage, N-stage, grade and
oestrogen receptors. Six out of 24 (25%) gp200-MR6-
negative cases had positive EGFRs compared with 12 out
of 24 (50%) cases expressing strong MR6 reactivity
(P=0.09). Tumour samples from women both younger and
older than 50 years had similar expression of gp200-MR6.
Relationship ofgp200-MR6 loss to survival
A univariate analysis of overall survival showed that the most
important prognostic factor was the nodal status (P<0.0001)
followed by T-stage (P=0.001), grade (P=0.09, NS) and
gp200-MR6 expression (P=0.09, NS). A multivariate
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Table I Correlation ofgp200-MR6 expression in 110 breast cancer
samples with different tumour parameters and patient age
gp200-MR6 gp200-MR6 gp200-MR6
Parameter (-) (w) (+) P-value
T-stage
<2cm 9 29 10
2-4cm 12 26 13 0.72
4cm 9 7 1
N-stage
0 11 27 14
1 -3 11 22 6 0.42
>4 2 13 4
Histology
Ductal 19 46 16
Lobular 5 6 1 0.03
Other 0 10 7
Grade (ductal)
I/II 13 25 10 0.94
III 7 19 7
Oestrogen receptors
Negative 12 33 12 0.94
Positive 12 29 12
EGFR
Negative 18 31 12 0.09
Positive 6 31 12
Age
< 51 4 23 9 0.16
> 50 20 39 15
w, weak; +, positive; , negative.
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Figure 2 Overall survival (a), local relapse-free survival (b) and
distant metastasis-free survival (c) with respect to gp200-MR6
status in 110 breast cancer patients.
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analysis showed that only T-stage and N-stage were
independent prognostic factors. The hazard ratio of gp200-
MR6-positive cases analysed for overall survival was 0.3
(CI=0.07-1.30, P=0.1). Twenty-two out of 24 (92%)
patients with tumours showing strong gp200-MR6 staining
are alive and 21 out of 24 were without disease up to the time
of analysis. Sixty-five out of 86 (76%) weak/negative cases
were alive at analysis. Adjuvant chemotherapy administration
was equally distributed among gp200-MR6 groups (P=0.2).
Twenty-six out of 86 gp200-MR6-weak/negative cases
received adjuvant chemotherapy compared with four out of
20 gp200-MR6-positive cases.
Figure 2a shows the Kaplan-Meier overall survival curves
for three groups of gp200-MR6 staining. Strong positive
staining was correlated with better survival, which was not
significant on the log-rank test (P= 0.10). The local relapse-
free survival was not different among groups (P=0.81)
(Figure 2b). The distant metastases-free survival was not
significantly different, although it was better in cases with
strong gp200-MR6 expression (P= 0.18) (Figure 2c). Analysis
of gp200-MR6 expression in node-positive and -negative
cases separately showed no effect on survival.
Discussion
Elevated expression of IL-4R has been reported in a variety
of tumour cell lines such as sarcomas and melanomas (Puri et
al., 1991; Obiri et al., 1994). In a preliminary study, Al
Jabaari et al. (1989) analysed the expression of MR6 on a
variety of normal and malignant tissues. Normal tissues
showed a negative or a weak positivity to MR6, and a variety
of different types of tumour tissues analysed were found to be
strongly positive. In that study, preliminary immunoscinti-
graphical data were also presented, suggesting that MR6 may
prove to be useful for in vivo imaging and targeting
immunotherapy.
More recently, we have reported in further detail on the
expression of gp200-MR6 in lung (Tungekar et al., 1991),
colon (Kaklamanis et al., 1992) and bladder (Tungekar et al.,
1996). In lung and colon, the expression of gp200-MR6 was
found to decrease with malignancy, and 30% of squamous
cell and adenocarcinoma lung cases were MR6-negative,
whereas all ten small-cell lung carcinomas were negative.
Positive staining was observed in 40 out of 44 colorectal
carcinomas, whereas all bladder carcinoma samples retained
their MR6 positivity. Thus, gp200-MR6 loss is associated
with malignancy in some but not all tumour cell lineages. In
breast cancer, it was found that approximately 50% of breast
carcinomas (24% of in situ, 69% of invasive tumours) had
reduced expression (Mat et al., 1993).
In this study, we have examined the expression of gp200-
MR6 in a large series of breast primary carcinomas to assess
the distribution of this molecule in greater detail and to
determine its significance in disease prognosis. Positive
staining (strong and weak) was observed in 86 out of 110
(78%) cases, while 24 out of 110 (22%) exhibited strong
positivity. This distribution of expression is in good
agreement with a previous study (Mat et al., 1993).
Menopausal status, tumour size, differentiation, nodal
status and oestrogen receptors were not correlated with
gp200-MR6 expression. These data suggest that gp200-MR6
status is not correlated with other known prognostic factors. A
lower risk for distant metastases was observed in patients with
positive gp200-MR6 expression. Taking into account our
observations that MR6 stains normal breast, colon and lung
epithelia, our data show that gp200-MR6 loss occurs during
cancer evolution. As the IL-4 receptor is the target of IL-4
produced by NK cells in breast cancerpatients (Lorenzen et al.,
1991), it seems likely that loss of the IL-4R-associated gp200-
MR6 'molecule could represent a mechanism oftumour escape
from immune surveillance. IL-4R is also relevant for IL-4/toxin
therapy (Debinski et al., 1993) and IL-4 is used as a growth
inhibitor. Like TGF, endogenous IL-4 may be inhibitory in
normal tissues, and loss ofIL-4 receptor or gp200-MR6 may be
related to progression.
In a recent study, we showed an increased HLA class I
antigenic loss in breast cancer metastatic to lymph nodes
compared with the primary tumours (Kaklamanis et al., 1995).
It would be of interest to examine whether cells metastatic to
lymph nodes or distant organs have a similarly higher
occurrence of gp200-MR6 loss. Short-term distant metastasis-
free survival was better in patients with MR6-positive tumours.
The combined role of HLA class I and IL-4R/gp200-MR6 in
survival ofbreast cancer patients requires further investigation.
Although expression ofgp200-MR6 on normalepithelia and
haemopoietic cells raises potential problems oftoxicity for the
use of radiolabelled and toxin-conjugated antibody and
cytokine targeting (Al Jabaari et al., 1989; Debinski et al.,
1993), the differences in IL-4R structure on these different cell
types may negate such problems (Murata et al., 1996;
Bamborough et al., 1993). Finally, although there are many
prognostic factors in breast cancer, none of them relate to
immunological pathways; the data presented in this study
suggest the potential of lymphokines as an infdependent
pathway regulating cancer growth.
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